Literature DB >> 16732758

Topiramate for smoking cessation.

Yasser Khazaal1, Jacques Cornuz, Romain Bilancioni, Daniele Fabio Zullino.   

Abstract

Due to its AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible-dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side-effects. Controlled trials are needed to confirm these preliminary observations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732758     DOI: 10.1111/j.1440-1819.2006.01518.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  15 in total

1.  Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes.

Authors:  Yasser Khazaal; Daniele Fabio Zullino
Journal:  Eur J Clin Pharmacol       Date:  2007-07-14       Impact factor: 2.953

2.  Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type.

Authors:  Andrea H Weinberger; Tony P George; Kenneth A Perkins; K N Roy Chengappa
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

Review 3.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

Review 4.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 5.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

6.  Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.

Authors:  Jason D Robinson; Yong Cui; Maher Karam-Hage; George Kypriotakis; Francesco Versace; Nassima Ait-Daoud Tiouririne; Robert M Anthenelli; Paul M Cinciripini
Journal:  Alcohol Clin Exp Res       Date:  2022-01-31       Impact factor: 3.455

Review 7.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

9.  Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

Authors:  Mikail Nourredine; Lucie Jurek; Bernard Angerville; Yannick Longuet; Julia de Ternay; Alain Derveaux; Benjamin Rolland
Journal:  CNS Drugs       Date:  2021-02-16       Impact factor: 5.749

Review 10.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.